Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Table 1

Characteristics of the included articles and the outcome/s.

Study	Study design and phase	Period of study	Country	Population and age (B vs. C)	Intervention	Comparator	Outcomes	Cochrane RoB
Horby et al. [12]	RCTs-open label and platform trial (factorial design)	Feb 21–Dec 21	1 (UK)	>100 centers/hospitals (58.5 vs. 57.7)	(i) 4 mg baricitinib for 10 days; (ii) Reduced dose in case of low eGFR (<60 mL/min) or patients taking probenecid or in children <9 years old	Usual care	Mortality: reduced; IMV: not reduced	High (due to open-label study design)
Kalil et al. [13]	Full RCTs and phase III trial	May–July 20	8 countries	67 centers (55 vs. 55.8)	(i) Baricitinib 4 mg (maximum 14 days) with remdesivir (maximum 10 days); (ii) Baricitinib 2 mg (with other health related problems) (maximum 14 days) with remdesivir (maximum 10 days)	Remdesivir	Mortality: not reduced; IMV/ECMO: reduced	Low
Marconi et al. [7]	Full RCTs and phase III trial	Jun 20–Jan 21	12 countries	>100 centers (57.8 vs. 57.5)	(i) Baricitinib 2 mg or 4 mg with matching SOC for maximum 14 days	Placebo with SOC	Mortality: reduced; IMV: not reduced	Low
Ely et al. [14]	Full RCTs and phase III trial	Dec 20–Apr 21	4 countries	18 centers (58.4 vs. 58.8)	(i) Baricitinib 2 mg or 4 mg with SOC for maximum of 14 days	Placebo with SOC	Mortality: reduced; IMV: NA	Low

IMV: invasive mechanical ventilation; SOC: standard of care; B: baricitinib; C: control; RoB: Risk of bias; UK: United Kingdom; eGFR: estimated glomerular filtration rate; ECMO: extracorporeal membrane oxygenation; NA: not available.